WO1996006620A3 - Lipid analogs for treating viral infections - Google Patents

Lipid analogs for treating viral infections Download PDF

Info

Publication number
WO1996006620A3
WO1996006620A3 PCT/US1995/010111 US9510111W WO9606620A3 WO 1996006620 A3 WO1996006620 A3 WO 1996006620A3 US 9510111 W US9510111 W US 9510111W WO 9606620 A3 WO9606620 A3 WO 9606620A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral infections
treating viral
lipid analogs
phospholipid
analogs
Prior art date
Application number
PCT/US1995/010111
Other languages
French (fr)
Other versions
WO1996006620A2 (en
Inventor
Louis S Kucera
Susan L Morris-Natschke
Khalid S Ishaq
Original Assignee
Univ Wake Forest
Univ North Carolina
Louis S Kucera
Morris Natschke Susan L
Khalid S Ishaq
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wake Forest, Univ North Carolina, Louis S Kucera, Morris Natschke Susan L, Khalid S Ishaq filed Critical Univ Wake Forest
Priority to EP95928365A priority Critical patent/EP0781138B1/en
Priority to JP50877396A priority patent/JP4259611B2/en
Priority to DE69535758T priority patent/DE69535758D1/en
Priority to AU32166/95A priority patent/AU3216695A/en
Priority to CA002197319A priority patent/CA2197319C/en
Priority to US08/793,470 priority patent/US5962437A/en
Publication of WO1996006620A2 publication Critical patent/WO1996006620A2/en
Publication of WO1996006620A3 publication Critical patent/WO1996006620A3/en
Priority to US09/412,539 priority patent/US7129227B1/en
Priority to US10/889,127 priority patent/US7135584B2/en
Priority to US10/943,923 priority patent/US7141557B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpesviruses, is disclosed. The method comprising administering to a subject in need of such treatment an infection-combating amount of a phospholipid or phospholipid derivative.
PCT/US1995/010111 1994-08-29 1995-08-07 Lipid analogs for treating viral infections WO1996006620A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP95928365A EP0781138B1 (en) 1994-08-29 1995-08-07 Lipid analogs for treating viral infections
JP50877396A JP4259611B2 (en) 1994-08-29 1995-08-07 Lipid analogues for treating viral infections
DE69535758T DE69535758D1 (en) 1994-08-29 1995-08-07 LIPID ANALOGUE FOR THE TREATMENT OF VIRAL INFECTIONS
AU32166/95A AU3216695A (en) 1994-08-29 1995-08-07 Lipid analogs for treating viral infections
CA002197319A CA2197319C (en) 1994-08-29 1995-08-07 Lipid analogs for treating viral infections
US08/793,470 US5962437A (en) 1994-08-29 1995-08-07 Lipid analogs for treating viral infections
US09/412,539 US7129227B1 (en) 1994-08-29 1999-10-04 Lipid analogs for treating viral infections
US10/889,127 US7135584B2 (en) 1995-08-07 2004-07-13 Lipid analogs for treating viral infections
US10/943,923 US7141557B2 (en) 1994-08-29 2004-09-20 Lipid analogs for treating viral infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29741694A 1994-08-29 1994-08-29
US08/297,416 1994-08-29
US31490194A 1994-09-29 1994-09-29
US08/314,901 1994-09-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US31490194A Continuation 1994-08-29 1994-09-29

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US08/793,470 A-371-Of-International US5962437A (en) 1994-08-29 1995-08-07 Lipid analogs for treating viral infections
US08793470 A-371-Of-International 1995-08-07
US09/412,539 Division US7129227B1 (en) 1994-08-29 1999-10-04 Lipid analogs for treating viral infections

Publications (2)

Publication Number Publication Date
WO1996006620A2 WO1996006620A2 (en) 1996-03-07
WO1996006620A3 true WO1996006620A3 (en) 1996-06-13

Family

ID=26970138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/010111 WO1996006620A2 (en) 1994-08-29 1995-08-07 Lipid analogs for treating viral infections

Country Status (8)

Country Link
US (6) US5962437A (en)
EP (2) EP0781138B1 (en)
JP (3) JP4259611B2 (en)
AT (1) ATE395922T1 (en)
AU (1) AU3216695A (en)
CA (1) CA2197319C (en)
DE (1) DE69535758D1 (en)
WO (1) WO1996006620A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
EP0781138B1 (en) * 1994-08-29 2008-05-21 Wake Forest University Lipid analogs for treating viral infections
DE19855963A1 (en) * 1998-12-04 2000-06-08 Herbert Schott Amphiphilic glyceryl nucleotides, process for their preparation and their use
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US7309696B2 (en) * 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
WO2003013573A1 (en) * 2001-08-10 2003-02-20 Epix Medical, Inc. Polypeptide conjugates with extended circulating half-lives
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
KR100871648B1 (en) 2001-08-31 2008-12-03 톰슨 라이센싱 Method of transmitting content, and method and apparatus for receiving and processing content
EP1436313B1 (en) 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
TWI342873B (en) * 2004-02-04 2011-06-01 Univ Kanagawa Calixarene compound, method for menufacturing same, intermediate of same, and composition containing same
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
LT2574341T (en) 2004-03-29 2017-09-11 University Of South Florida Effective treatment of tumors and cancer with triciribine phosphate
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US20070003608A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
JP2008535862A (en) * 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド Compounds, compositions and methods for the treatment of poxvirus infections
JP5320284B2 (en) 2006-05-03 2013-10-23 キメリクス，インコーポレーテッド Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
EP2596799B1 (en) 2007-02-08 2016-11-23 University of Utah Research Foundation Methods and compositions related to inhibition of viral entry
EP2070938A1 (en) 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
MX2010008148A (en) * 2008-01-25 2010-10-20 Chimerix Inc Methods of treating viral infections.
JP5752599B2 (en) * 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド Oxidized lipid compounds and uses thereof
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
EP3216789A1 (en) 2010-02-12 2017-09-13 Chimerix, Inc. Methods of treating viral infection
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
CA2868735C (en) * 2011-03-28 2020-02-25 University Of Utah Research Foundation D-peptide conjugates comprising a membrane localizing potency-enhancing cargo molecule for inhibiting hiv entry
JP6717825B2 (en) 2014-11-26 2020-07-08 バスキュラー バイオジェニックス リミテッド Oxidized lipids and methods for treating or preventing fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CA3010713A1 (en) 2016-01-07 2017-07-13 Navigen, Inc. D-peptide inhibitors of hiv entry and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3934820A1 (en) * 1989-10-19 1991-04-25 Boehringer Mannheim Gmbh USE OF LECITHIN ANALOGA AS AN ANTIVIRAL MEDICINAL PRODUCT AND NEW DERIVATIVES
WO1991009602A2 (en) * 1989-12-23 1991-07-11 Boehringer Mannheim Gmbh Use of alkyl phospholipids as antiviral drugs, as well as new compounds
DE4010228A1 (en) * 1990-03-30 1991-10-02 Werner E G Prof Dr Mueller Prepn. of antiviral, esp. anti-AIDS agent - by mixing halo-contg. higher alkyl-glycerol-phospho-choline analogues with suitable carrier

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2108765A (en) * 1938-02-15 Preserving and disinfecting media
US2086585A (en) * 1933-04-13 1937-07-13 Alba Pharmaceutical Company In Quaternary ammonium compounds
US2087132A (en) * 1933-04-13 1937-07-13 Alba Pharmaceutical Company In Quaternary ammonium compounds
US2209383A (en) * 1938-03-05 1940-07-30 Rohm & Haas Process of waterproofing fabrics
US2445393A (en) * 1944-03-08 1948-07-20 Rhone Poulenc Sa New amino-derivatives of dioxa-cyclopentane
US2439969A (en) * 1944-04-17 1948-04-20 Rhone Poulenc Sa Amino-dioxacyclopentanes
US2513747A (en) * 1945-10-04 1950-07-04 Ciba Ltd Cyclic amino-acetals
US2606909A (en) * 1947-08-01 1952-08-12 Univ Michigan Basic dioxolanes
US2689790A (en) * 1951-09-26 1954-09-21 Monsanto Chemicals Nitrogenous compound herbicides
NL189533C (en) * 1953-07-29 Ates Componenti Elettron PROCEDURE FOR APPLYING A PLASTIC HOLDER WITH HEAT DISCHARGE AROUND AN INTEGRATED CIRCUIT, AS WELL AS COMBINATION OF A MOLD AND A HEAT DISCHARGE ELEMENT FOR USE IN THIS PROCEDURE.
US3054678A (en) * 1958-04-16 1962-09-18 Michener Harold David Preservation process with quaternary ammonium compounds
DE1619043B2 (en) * 1967-04-07 1977-11-03 Hoechst Ag, 6000 Frankfurt AGENT FOR SOFTENING TEXTILES AND AT THE SAME TIME PROVIDING GOOD ABSORPTION
US4119714A (en) * 1970-02-27 1978-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens
DE2033359C3 (en) * 1970-07-06 1980-02-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Acylpropanediol- (1,3) -phosphoric acid monocholine ester and process for their preparation
JPS49100224A (en) * 1973-01-29 1974-09-21
US4093714A (en) * 1974-03-15 1978-06-06 Icn Pharmaceuticals, Inc. 9β-D-Arabinofuranosylpurine nucleotides and method of use
US4159988A (en) * 1974-08-06 1979-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic phospholipids, a process for their manufacture and their use
FR2356425A1 (en) * 1976-07-01 1978-01-27 Roussel Uclaf APPLICATION AS MEDICINAL PRODUCTS FROM ORGANIC DERIVATIVES OF MONTMORILLONITE
US4291024A (en) 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
DE2820893C2 (en) 1978-05-12 1986-02-20 A. Nattermann & Cie GmbH, 5000 Köln Structural analogs of natural phospholipids and processes for making these compounds
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4444766A (en) * 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
DE3039629A1 (en) * 1980-10-21 1982-06-03 Boehringer Mannheim Gmbh, 6800 Mannheim Alkanol phosphoric acid mono-ammonium alkyl ester(s) - are cancerostatic phospholipid(s) which do not cause thrombocyte aggregation
JPS5772914A (en) * 1980-10-22 1982-05-07 Takeda Chem Ind Ltd Antitumor agent
US4471113A (en) * 1982-02-03 1984-09-11 The United States Of America As Represented By The Department Of Energy Prodrugs based on phospholipid-nucleoside conjugates
EP0094586A3 (en) * 1982-05-13 1984-06-06 Ono Pharmaceutical Co., Ltd. Glycerol derivatives, process for preparing same and pharmaceutical composition containing same
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
JPS5988447A (en) * 1982-11-11 1984-05-22 Ono Pharmaceut Co Ltd Glycerol derivative, its production and agent containing said derivative
FR2540122B1 (en) * 1983-01-27 1985-11-29 Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
JPS6081193A (en) * 1983-10-11 1985-05-09 Takeda Chem Ind Ltd Phospholipid
JPS60100544A (en) * 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd Novel glycerin derivative, its preparation and drug containing it
JPS60104066A (en) * 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd Glycerin derivative, its preparation, and drug containing it
JPS60105650A (en) * 1983-11-14 1985-06-11 Ono Pharmaceut Co Ltd Glycerol derivative, production thereof and pharmaceutical containing said derivative
US4540521A (en) * 1984-01-16 1985-09-10 National Distillers And Chemical Corporation Liquid quaternary ammonium antistatic compositions
US4622392A (en) 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
JPS6124519A (en) * 1984-07-11 1986-02-03 Takeda Chem Ind Ltd Antitumor agent
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
FR2580283B1 (en) 1985-04-15 1989-11-24 Toyo Jozo Kk NEW NUCLEOSIDE-PHOSPHOLIPIDE CONJUGATE
JPS61238793A (en) 1985-04-17 1986-10-24 Toyo Jozo Co Ltd Novel phospholipid derivative
US4619917A (en) * 1985-07-18 1986-10-28 Sandoz Pharm. Corp. Substituted 2-furanyl- or 5-oxo-2-furanyl methoxy phosphoryl alkyl cyclimmonium salts
CA1280369C (en) * 1985-12-04 1991-02-19 Hansjorg Eibl Pharmaceutical with anti-tumor effect
US4841039A (en) * 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
DE3619748A1 (en) * 1986-06-12 1987-12-17 Merz & Co Gmbh & Co ANTIMICROBIAL AGENTS
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
EP0262876B1 (en) 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPS6429319A (en) * 1987-07-23 1989-01-31 Toyama Chemical Co Ltd Antiviral agent containing lysolecithin and phospholipid
DE3726945A1 (en) * 1987-08-13 1989-02-23 Dietl Hans L-Carnitine derivatives of valproic acid and pharmaceuticals containing these
US4894389A (en) * 1987-10-02 1990-01-16 Merrell Dow Pharmaceuticals Inc. Novel aminoalkyl-substituted heterocyclic sulfur compounds
US4997761A (en) 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
EP0335396A1 (en) * 1988-04-01 1989-10-04 MAGIS FARMACEUTICI S.p.A. Glycero-phosphoric and -diphosphoric acids derivatives of L-carnitine or L-carnitine esters
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
JPH01293129A (en) 1988-05-20 1989-11-27 Kobe Steel Ltd Continuous high temperature and high pressure treatment device
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
EP0348859A1 (en) * 1988-07-01 1990-01-03 MAGIS FARMACEUTICI S.p.A. 1,2-di-O-acyl glycero(DI)phosphate of L-carnitine and its derivatives, a process for their preparation and pharmaceutical formulations which contain them
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CA2001401A1 (en) 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GB8827337D0 (en) * 1988-11-23 1988-12-29 Medical Res Council Nucleoside analogues
US5221696A (en) 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
FI902821A0 (en) * 1989-06-12 1990-06-06 Res Found Mental Hygiene FOERMINSKNING AV INFEKTIONSSPRIDNING MEDELST BLODBEHANDLINGSAPPARATUR.
DE3929217A1 (en) * 1989-09-02 1991-03-07 Boehringer Mannheim Gmbh USE OF PHOSPHOLIPID DERIVATIVES AS ANTIVIRAL MEDICINAL PRODUCTS AND NEW PHOSPHOLIPIDES
GR1000688B (en) * 1989-12-22 1992-10-08 Sod Conseils Rech Applic Glycerine derivatives preparation method
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB2239243B (en) 1989-12-22 1993-05-12 Scras Glycerol derivatives
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
EP0531452A4 (en) * 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ATE137242T1 (en) * 1990-06-15 1996-05-15 Univ Wake Forest COVALENT-THER LIPIDENUCLEOSIDE CONJUGATES
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
DE4026265A1 (en) * 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh NEW PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES, THEIR PRODUCTION AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS
WO1992004887A1 (en) * 1990-09-25 1992-04-02 Kyowa Hakko Kogyo Co., Ltd. Induction of cytotoxic t cell
CA2093816A1 (en) * 1990-10-09 1992-04-10 Michael J. Scolaro Inhibition of viral replication
EP0594677A4 (en) 1991-07-12 1997-09-17 Vical Inc Antiviral liponucleosides: treatment of hepatitis b
CA2122246C (en) * 1991-10-28 1999-04-27 Dennis L. Fost Phospholipid antimicrobial compositions
DE4204031A1 (en) * 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh NEW LIPID PHOSPHONIC ACID-NUCLEOSIDE CONJUGATES AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS
DE4204032A1 (en) * 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh NEW LIPONUCLEOTIDES, THEIR PRODUCTION AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US6602861B1 (en) * 1992-04-16 2003-08-05 Research Corporation Technologies, Inc. Acylated phospholipid drugs
US5512671A (en) 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
WO1994019012A2 (en) 1993-02-24 1994-09-01 Wang Jui H Compositions and methods of application of reactive antiviral polymers
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
WO1994028908A2 (en) 1993-06-10 1994-12-22 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
ATE199906T1 (en) * 1993-06-29 2001-04-15 Mitsubishi Chem Corp PHOSPHONATE NUCLEOTIDE ESTER DERIVATIVES
CA2167537A1 (en) 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
EP0781138B1 (en) * 1994-08-29 2008-05-21 Wake Forest University Lipid analogs for treating viral infections
JP3786447B2 (en) 1995-03-31 2006-06-14 エーザイ株式会社 Preventive and therapeutic agent for hepatitis C
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
JP3927630B2 (en) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 Preventive and therapeutic agents for viral infections
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
JPH10293129A (en) 1997-04-18 1998-11-04 Nof Corp Method for measuring endotoxin in phospholipid
EP1009732B1 (en) 1997-06-30 2003-05-21 MERZ + CO. GmbH & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
JP4213841B2 (en) 2000-03-23 2009-01-21 大成建設株式会社 Temporary bearing construction method
PT1241432E (en) 2001-03-15 2006-12-29 Teijin Twaron Gmbh Penetration-resistant material comprising fabric with high linear density ratio of two sets of threads

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3934820A1 (en) * 1989-10-19 1991-04-25 Boehringer Mannheim Gmbh USE OF LECITHIN ANALOGA AS AN ANTIVIRAL MEDICINAL PRODUCT AND NEW DERIVATIVES
WO1991009602A2 (en) * 1989-12-23 1991-07-11 Boehringer Mannheim Gmbh Use of alkyl phospholipids as antiviral drugs, as well as new compounds
DE4010228A1 (en) * 1990-03-30 1991-10-02 Werner E G Prof Dr Mueller Prepn. of antiviral, esp. anti-AIDS agent - by mixing halo-contg. higher alkyl-glycerol-phospho-choline analogues with suitable carrier

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"In vitro evaluation of phosphocholine and quaternary ammonium containing lipids as novel anti-HIV agents", J.MED.CHEM., vol. 34, no. 4, pages 1377 - 83 *
"Membrane interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp 120 binding to monoclonal antibody", AIDS RES. HUM. RETROVIRUSES, vol. 11, no. 6, pages 705 - 712 *

Also Published As

Publication number Publication date
US7294620B2 (en) 2007-11-13
JP2011051996A (en) 2011-03-17
JP2007056033A (en) 2007-03-08
JP4259611B2 (en) 2009-04-30
US20050080050A1 (en) 2005-04-14
DE69535758D1 (en) 2008-07-03
US8106032B2 (en) 2012-01-31
EP1852121A2 (en) 2007-11-07
US20070099870A1 (en) 2007-05-03
EP0781138A2 (en) 1997-07-02
US7141557B2 (en) 2006-11-28
AU3216695A (en) 1996-03-22
US7294621B2 (en) 2007-11-13
CA2197319A1 (en) 1996-03-07
WO1996006620A2 (en) 1996-03-07
ATE395922T1 (en) 2008-06-15
EP1852121A3 (en) 2007-11-21
JPH10506619A (en) 1998-06-30
US7129227B1 (en) 2006-10-31
EP0781138B1 (en) 2008-05-21
CA2197319C (en) 2009-01-27
US20080293667A1 (en) 2008-11-27
US20070105812A1 (en) 2007-05-10
US5962437A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
WO1996006620A3 (en) Lipid analogs for treating viral infections
AU7044894A (en) (phospho)lipids for combatting hepatitis b virus infection
WO2001090121A3 (en) Methods and compositions for treating hepatitis c virus
IL153078A0 (en) Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
PL297849A1 (en) Vaccine against and method of treating the patients infectedwith hiv virus
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
AU3530293A (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
CA2189705A1 (en) Use of flupirtine for the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
CA2142862A1 (en) Method for Inhibiting HIV Replication Using IL-4
ES2014042A6 (en) Composition and method for treating hepatitis virus infections using 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-ethyluracil.
WO1993014760A3 (en) Methods
AU2396900A (en) Treatment and prevention of hiv and other viral infections
AU3593095A (en) Method of treatment of human immunodeficiency virus (hiv) infection
AU6447690A (en) Method of administering soluble t4 for treatment of human immunodeficiency virus infection
WO1996013263A3 (en) Methods of treatment of viral disease with inhibitors of sphingolipid biosynthesis
AU6247896A (en) Method for preparing sulphate esters effective in the treatment of hiv (human immunodeficiency virus) infections, and aids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2197319

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995928365

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08793470

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995928365

Country of ref document: EP